Cohen & Steers Inc (NYSE:CNS) Misses Q2 2025 Earnings and Revenue Estimates

Last update:

Cohen & Steers Inc (NYSE:CNS) reported its second-quarter 2025 earnings, missing analyst expectations on both revenue and earnings per share (EPS). The investment manager, specializing in real assets and alternative income solutions, posted revenue of $136.13 million, falling short of the estimated $137.75 million. Similarly, EPS came in at $0.73, below the consensus estimate of $0.76.

Key Earnings Highlights

Revenue: $136.13M (actual) vs. $137.75M (estimated) – a 1.2% miss
EPS: $0.73 (actual) vs. $0.76 (estimated) – a 4.3% miss
After-Market Reaction: Shares dipped -0.49%, reflecting investor disappointment.

Market Performance Context

The stock has shown mixed performance recently:

Last Week: -2.6%
Last Two Weeks: -2.97%
Last Month: +2.12%

The muted reaction in extended trading suggests the market had already priced in some caution ahead of earnings, though the slight decline indicates lingering concerns over the miss.

Forward-Looking Estimates

Analysts project the following for Cohen & Steers:

Q3 2025 Revenue Estimate: $140.77M
Q3 2025 EPS Estimate: $0.78
Full-Year 2025 Revenue Estimate: $552.41M
Full-Year 2025 EPS Estimate: $3.08

The company did not provide explicit guidance in its press release, leaving investors to rely on analyst expectations. The absence of an upward revision in outlook may have contributed to the subdued after-hours reaction.

Press Release Summary

The earnings release reiterated Cohen & Steers' focus on liquid real assets, including real estate securities and infrastructure investments. The firm highlighted its diversified distribution channels—spanning wealth management and institutional clients—but did not signal any major strategic shifts or unexpected developments.

For a deeper dive into Cohen & Steers' earnings history and future estimates, see the full earnings and estimates breakdown here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.